PTL exhibits effective and selective anti-CLL activity in vitro, targeting CLL cells irrespective of their p53 status, owing to its pro-oxidant properties (Agathanggelou et al., 2015). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.